(Q37350360)

19 August 2017

1 reference

title

Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses (English)

1 reference

19 August 2017

Ilya Frolov

2

0 references

Douglas G Widman

object named as

Douglas G Widman

series ordinal

1

0 references

author name string

Peter W Mason

series ordinal

3

1 reference

19 August 2017

1 January 2008

1 reference

Advances in Virus Research

19 August 2017

1 reference

19 August 2017

72

1 reference

19 August 2017

77-126

1 reference

Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Japanese encephalitis and dengue vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Yellow fever vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Current status of flavivirus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

History of TBE vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

History of thymoma and yellow fever vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Early Production of Type I Interferon during West Nile Virus Infection: Role for Lymphoid Tissues in IRF3-Independent Interferon Production

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction of intertypic chimeric dengue viruses by substitution of structural protein genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

1 reference

7 January 2021

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Recent advancement in flavivirus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Japanese encephalitis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Replication-defective viruses as vaccines and vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue fever, Hawaii, 2001-2002

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Promise of new Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Acute disseminated myelitis after Japanese B encephalitis vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Incorporation of Tick-Borne Encephalitis Virus Replicons into Virus-Like Particles by a Packaging Cell Line

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

The continuing spread of West Nile virus in the western hemisphere

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Neutralization and antibody-dependent enhancement of dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

1 reference

7 January 2021

Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. II. Attributes of virus cloned at different dog kidney passage levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Acute viscerotropic disease following vaccination against yellow fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Protection against Japanese encephalitis by inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction and applications of yellow fever virus replicons.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Mimicking live flavivirus immunization with a noninfectious RNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Stable High-Producer Cell Clone Expressing Virus-Like Particles of the Japanese Encephalitis Virus E Protein for a Second-Generation Subunit Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A recombinant envelope protein vaccine against West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Preparation and immunogenic properties of a recombinant West Nile subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Isolation of Plaque Variants Differing in Virulence from the 17D Strain of Yellow Fever Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Expression of Japanese encephalitis virus antigens in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Production and characterization of vaccines based on flaviviruses defective in replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Treatment of yellow fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A live, attenuated recombinant West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Unravelling the neuropathogenesis of Japanese encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Japanese encephalitis for a reference to international travelers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Allergic reactions to Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Neurological complications and Japanese encephalitis vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area--impact on current recommendations for immunization of high-risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immunology and immunopathogenesis of dengue disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Research on dengue during World War II

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

trans-Packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

The long-term outcomes of human West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Production of Pseudoinfectious Yellow Fever Virus with a Two-Component Genome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Studies on the nature of dengue viruses. I. Correlation of particle density, infectivity, and RNA content of type 2 virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

The use of yellow fever virus modified by in vitro cultivation for human immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immunization of mice against West Nile virus with recombinant envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Construction and application of chimeric virus-like particles of tick-borne encephalitis virus and mosquito-borne Japanese encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue Virions and Antigens in Brain and Serum of Infected Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Immune response in rabbits to virion and nonvirion antigens of the Flavivirus kunjin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

Physical and biological properties of dengue-2 virus and associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2808%2900402-8

7 January 2021

10.1016/S0065-3527(08)00402-8

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

19081489